Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Hepatology - United States
doi 10.1002/hep.30337
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and the ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice

Cancers
Cancer ResearchOncology
2019English

Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges

Immunotherapy
OncologyAllergyImmunology
2016English

Nanomedicine in Management of Hepatocellular Carcinoma: Challenges and Opportunities

International Journal of Cancer
Cancer ResearchOncology
2016English

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Promises and Challenges

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

Trends in the Development of MET Inhibitors for Hepatocellular Carcinoma

Future Oncology
MedicineCancer ResearchOncology
2016English

Efficacy and Safety of Immune Checkpoint Therapy in Hepatocellular Carcinoma: Meta-Analysis

Hepatoma Research
2019English

Biomarkers for Immune Checkpoint Inhibitors: The Importance of Tumor Topography and the Challenges to Cytopathology

Cancer cytopathology
Cancer ResearchOncology
2017English

Immune Checkpoint Inhibitors and irAEs

Trends in Immunotherapy
2018English

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy